SEC Form DFiling only, no announcement found
Alzheon, based in Framingham, MA, reported $78,797,184 sold in a private offering of equity, with the first sale on August 26, 2026, in a Form D filed with the SEC on September 10, 2026. The filing says 3 investors have already invested. The offering authorizes up to $499,999,999.
Legal name on the filing: ALZHEON, INC..
| Amount sold | $78,797,184Basis: Form D total amount sold, as of the filing of September 10, 2026. Not the announced round size. |
|---|---|
| Total offering | $499,999,999The most the company may sell under this offering. Not money raised. |
| Remaining to be sold | $421,202,815 |
| Securities offered | Equity |
| Exemption claimed | Rule 506(b) |
| Date of first sale | August 26, 2026 |
| Investors already invested | 3 |
| Non-accredited investors | None |
| Minimum investment accepted | $0 |
| Part of a merger or acquisition | No |
| Industry group | Biotechnology |
| Principal place of business | Framingham, MA |
| Jurisdiction of incorporation | DELAWARE |
| Entity type | Corporation |
| Year of incorporation | over five years ago |
| Revenue range | Decline to Disclose |
| SEC CIK | 1582636 |
Round name, valuation, lead investor and participants are not on a Form D, so they are not shown. They appear here only when a press or company announcement is matched to this deal.
| Name, as filed | Relationship | VC Beast profile |
|---|---|---|
| Martin Tolar, M.D., Ph.D. | Executive Officer, DirectorPresident and Chief Executive Officer | None linked |
| Christopher Noel Dunn | Director | None linked |
| Neil W. Flanzraich | Director | None linked |
| Jordan Heller | Director | None linked |
| Diane K. Jorkasky, M.D. | Director | None linked |
| Gino Santini | Director | None linked |
| Muneer Satter | Director | None linked |
| Kenneth Mace | Executive OfficerTreasurer and Chief Financial Officer | None linked |
| Susan Abushakra, M.D. | Executive OfficerChief Medical Officer | None linked |
| John Hey, Ph.D. | Executive OfficerChief Scientific Officer | None linked |
| Aidan Power, MRCPsych | Executive OfficerChief Development Officer | None linked |
| Adem Albayrak | Executive OfficerChief Data Officer | None linked |
Form D lists the company's executive officers, directors and promoters. A director is often an investor's board representative, but the filing does not say who invested.
| Filed | Form | Amount sold | Total offering |
|---|---|---|---|
| Sep 10, 2026 | D (original) | $78,797,184 | $499,999,999 |
The latest filing states the current amount sold; an amendment replaces the figure before it.
From the issuer's EDGAR filing history. Amounts are shown for filings in our warehouse, which holds operating-company filings from July 16, 2026.
Filing only, no announcement found. The only source for this deal is the company's own SEC filing, made under penalty of law. When a press or company announcement is matched to it, it is cited here with the round name it gives.
Amount sold is the filing's total amount sold; total offering is its authorized maximum. This page was built from filings received through September 29, 2026. Report an error on the corrections page.
Cite this deal
VC Beast, "Alzheon: SEC Form D deal record", https://vcbeast.com/deals/alzheon-form-d-2026-08-26. Source: SEC EDGAR, accession 0001582636-26-000002.